Exicure Shares Are Trading Higher After the Company Announced It Entered Into a Patent License Agreement With Bluejay Therapeutics to Develop Cavrotolimod for the Potential Treatment for Hepatitis
Exicure宣布与Bluejay Therapeutics签订专利许可协议，开发用于潜在肝炎治疗的卡夫罗托莫德后，该公司股价走高